Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in French pharma major Sanofi's strategy. Sanofi announced today the closing of the sale to US private ...

The US Food and Drug Administration (FDA) has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella. Opella had launched the actual use trial ...

Opella Enterogermina challenges Murphy's Law which states that “anything that can go wrong, will go wrong” and questions the ...

The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q2Stay Ahead of the Market: Discover outperforming ...

Marketers are growing more comfortable with letting generative artificial intelligence assume the voices of their brands.The work often involves AI agents, which are a series of interconnected AI ...

Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially. The French pharma group confirmed ...

Sanofi is now in exclusive talks with private equity company Clayton Dubilier & Rice over the sale of a controlling stake in its consumer health business Opella, as the French government seeks to ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling ...